Collegium Pharmaceutical (COLL) Stock Forecast, Price Target & Predictions
COLL Stock Forecast
Collegium Pharmaceutical stock forecast is as follows: an average price target of $41.50 (represents a 24.03% upside from COLL’s last price of $33.46) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
COLL Price Target
The average price target for Collegium Pharmaceutical (COLL) is $41.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $50.00 to $35.00. This represents a potential 24.03% upside from COLL's last price of $33.46.
COLL Analyst Ratings
According to 8 Wall Street analysts, Collegium Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for COLL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 2 'Hold' (25.00%), 1 'Sell' (12.50%), and 0 'Strong Sell' (0.00%).
Collegium Pharmaceutical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Oren Livnat | H.C. Wainwright | $50.00 | $38.65 | 29.37% | 49.43% |
| Aug 09, 2024 | David Amsellem | Piper Sandler | $37.00 | $34.63 | 6.86% | 10.58% |
| Jul 30, 2024 | Oren Livnat | H.C. Wainwright | $47.00 | $38.60 | 21.76% | 40.47% |
| Jun 07, 2024 | Glen Santangelo | Jefferies | $44.00 | $31.36 | 40.31% | 31.50% |
| May 10, 2024 | David Amsellem | Piper Sandler | $39.00 | $33.11 | 17.79% | 16.56% |
| Jan 05, 2023 | - | Needham | $35.00 | $26.98 | 29.73% | 4.60% |
The latest Collegium Pharmaceutical stock forecast, released on Sep 04, 2024 by Oren Livnat from H.C. Wainwright, set a price target of $50.00, which represents a 29.37% increase from the stock price at the time of the forecast ($38.65), and a 49.43% increase from COLL last price ($33.46).
Collegium Pharmaceutical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 5 |
| Avg Price Target | - | $43.50 | $43.40 |
| Last Closing Price | $33.46 | $33.46 | $33.46 |
| Upside/Downside | -100.00% | 30.01% | 29.71% |
In the current month, the average price target of Collegium Pharmaceutical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Collegium Pharmaceutical's last price of $33.46. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 05, 2024 | Piper Sandler | Buy | Buy | Hold |
| Sep 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 05, 2024 | Susquehanna | - | Negative | Downgrade |
| Sep 05, 2024 | Needham | Buy | Buy | Hold |
| Sep 05, 2024 | BMO Capital | - | Market Perform | Downgrade |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 09, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Jul 30, 2024 | H.C. Wainwright | - | Buy | Upgrade |
| Jun 07, 2024 | Jefferies | Underperform | Buy | Upgrade |
Collegium Pharmaceutical's last stock rating was published by Piper Sandler on Oct 11, 2024. The company gave COLL a "Neutral" rating, the same as its previous rate.
Collegium Pharmaceutical Financial Forecast
Collegium Pharmaceutical Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $136.71M | $135.55M | $144.77M | $129.62M | $127.01M | $123.55M | $83.75M | $27.36M | $78.84M | $82.94M | $87.72M | $76.27M | $79.18M | $78.06M | $76.51M | $74.20M | $72.94M | $75.04M | $74.52M | $63.75M | $2.17M |
| Avg Forecast | $191.83M | $186.82M | $181.51M | $178.61M | $179.59M | $155.65M | $143.94M | $146.94M | $147.86M | $137.27M | $138.46M | $138.36M | $125.22M | $124.38M | $121.13M | $78.67M | $81.53M | $85.06M | $84.61M | $81.78M | $77.43M | $77.45M | $74.42M | $76.65M | $73.37M | $74.42M | $75.85M | $70.30M | $54.80M | $2.69M |
| High Forecast | $191.83M | $186.82M | $181.51M | $178.61M | $179.59M | $169.96M | $143.94M | $147.24M | $148.74M | $141.36M | $138.46M | $138.36M | $125.22M | $124.38M | $121.13M | $78.67M | $81.53M | $85.06M | $84.61M | $81.78M | $77.43M | $77.45M | $74.42M | $76.65M | $73.37M | $74.42M | $75.85M | $70.30M | $65.76M | $3.23M |
| Low Forecast | $191.83M | $186.82M | $181.51M | $178.61M | $179.59M | $148.70M | $143.94M | $146.63M | $146.15M | $130.89M | $138.46M | $138.36M | $125.22M | $124.38M | $121.13M | $78.67M | $81.53M | $85.06M | $84.61M | $81.78M | $77.43M | $77.45M | $74.42M | $76.65M | $73.37M | $74.42M | $75.85M | $70.30M | $43.84M | $2.16M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.00% | 0.98% | 1.05% | 1.04% | 1.02% | 1.02% | 1.06% | 0.34% | 0.93% | 0.98% | 1.07% | 0.99% | 1.02% | 1.05% | 1.00% | 1.01% | 0.98% | 0.99% | 1.06% | 1.16% | 0.81% |
Collegium Pharmaceutical's average Quarter revenue forecast for Dec 23 based on 3 analysts is $147.86M, with a low forecast of $146.15M, and a high forecast of $148.74M. COLL's average Quarter revenue forecast represents a 8.16% increase compared to the company's last Quarter revenue of $136.71M (Sep 23).
Collegium Pharmaceutical EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | $45.01M | $35.63M | $65.66M | $12.78M | $58.52M | $49.27M | $9.63M | $-29.54M | $31.40M | $33.63M | $38.43M | $32.08M | $36.62M | $33.55M | $15.77M | $1.89M | $-2.01M | $-617.00K | $-5.59M | $17.06M | $-22.97M |
| Avg Forecast | $32.55M | $31.70M | $30.80M | $30.31M | $30.47M | $26.41M | $24.42M | $15.84M | $25.09M | $23.29M | $23.49M | $14.40M | $-47.92M | $21.11M | $20.55M | $13.09M | $13.83M | $14.43M | $14.36M | $24.34M | $13.14M | $13.14M | $12.63M | $28.00M | $12.45M | $12.63M | $12.87M | $-4.43M | $14.27M | $-27.19M |
| High Forecast | $32.55M | $31.70M | $30.80M | $30.31M | $30.47M | $28.84M | $24.42M | $19.01M | $25.24M | $23.99M | $23.49M | $17.28M | $-38.33M | $21.11M | $20.55M | $15.71M | $13.83M | $14.43M | $14.36M | $29.21M | $13.14M | $13.14M | $12.63M | $33.59M | $12.45M | $12.63M | $12.87M | $-3.54M | $17.13M | $-21.75M |
| Low Forecast | $32.55M | $31.70M | $30.80M | $30.31M | $30.47M | $25.23M | $24.42M | $12.67M | $24.80M | $22.21M | $23.49M | $11.52M | $-57.50M | $21.11M | $20.55M | $10.47M | $13.83M | $14.43M | $14.36M | $19.47M | $13.14M | $13.14M | $12.63M | $22.40M | $12.45M | $12.63M | $12.87M | $-5.31M | $11.42M | $-32.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.93% | 1.52% | 4.56% | -0.27% | 2.77% | 2.40% | 0.74% | -2.14% | 2.18% | 2.34% | 1.58% | 2.44% | 2.79% | 2.66% | 0.56% | 0.15% | -0.16% | -0.05% | 1.26% | 1.20% | 0.84% |
3 analysts predict COLL's average Quarter EBITDA for Dec 23 to be $25.09M, with a high of $25.24M and a low of $24.80M. This is -44.26% lower than Collegium Pharmaceutical's previous annual EBITDA (Sep 23) of $45.01M.
Collegium Pharmaceutical Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | $20.63M | $13.01M | $-17.43M | $-7.20M | $457.00K | $-5.19M | $-13.07M | $-25.03M | $8.05M | $72.84M | $15.66M | $6.96M | $11.29M | $8.06M | $450.00K | $-2.41M | $-5.84M | $-4.71M | $-9.41M | $-18.65M | $-22.88M |
| Avg Forecast | $75.44M | $71.48M | $68.15M | $65.52M | $66.92M | $64.27M | $59.97M | $-21.51M | $55.66M | $49.19M | $49.19M | $-19.55M | $-70.98M | $55.80M | $58.15M | $-17.77M | $42.07M | $38.77M | $38.88M | $9.92M | $39.00M | $36.29M | $34.67M | $799.05K | $2.02M | $2.13M | $-1.82M | $-7.68M | $-15.61M | $-27.55M |
| High Forecast | $75.44M | $71.48M | $68.15M | $65.52M | $66.92M | $71.24M | $59.97M | $-17.21M | $61.94M | $56.76M | $49.71M | $-15.64M | $-56.78M | $58.02M | $58.15M | $-14.22M | $42.07M | $38.77M | $39.86M | $11.90M | $39.00M | $36.29M | $34.67M | $958.86K | $2.02M | $2.13M | $-1.82M | $-6.14M | $-12.49M | $-22.04M |
| Low Forecast | $75.44M | $71.48M | $68.15M | $65.52M | $66.92M | $58.85M | $59.97M | $-25.81M | $48.13M | $44.46M | $48.67M | $-23.46M | $-85.17M | $53.58M | $58.15M | $-21.33M | $42.07M | $38.77M | $37.91M | $7.94M | $39.00M | $36.29M | $34.67M | $639.24K | $2.02M | $2.13M | $-1.82M | $-9.21M | $-18.73M | $-33.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.42% | 0.26% | 0.89% | 0.10% | 0.01% | -0.09% | 0.74% | -0.60% | 0.21% | 1.87% | 1.58% | 0.18% | 0.31% | 0.23% | 0.56% | -1.19% | -2.74% | 2.59% | 1.23% | 1.20% | 0.83% |
Collegium Pharmaceutical's average Quarter net income forecast for Dec 23 is $55.66M, with a range of $48.13M to $61.94M. COLL's average Quarter net income forecast represents a 169.76% increase compared to the company's last Quarter net income of $20.63M (Sep 23).
Collegium Pharmaceutical SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | $35.30M | $38.19M | $52.77M | $38.03M | $38.37M | $41.25M | $54.53M | $26.60M | $30.51M | $30.37M | $31.48M | $26.82M | $26.43M | $29.32M | $31.26M | $25.09M | $30.07M | $28.93M | $32.35M | $31.58M | $22.85M |
| Avg Forecast | $70.65M | $68.80M | $66.84M | $65.78M | $66.14M | $57.32M | $53.01M | $89.73M | $54.45M | $50.55M | $50.99M | $81.57M | $75.42M | $45.81M | $44.61M | $74.16M | $30.03M | $31.33M | $31.16M | $19.93M | $28.51M | $28.52M | $27.41M | $55.51M | $27.02M | $27.41M | $27.93M | $25.61M | $26.43M | $992.27K |
| High Forecast | $70.65M | $68.80M | $66.84M | $65.78M | $66.14M | $62.59M | $53.01M | $107.68M | $54.78M | $52.06M | $50.99M | $97.89M | $90.51M | $45.81M | $44.61M | $88.99M | $30.03M | $31.33M | $31.16M | $23.92M | $28.51M | $28.52M | $27.41M | $66.61M | $27.02M | $27.41M | $27.93M | $30.73M | $31.71M | $1.19M |
| Low Forecast | $70.65M | $68.80M | $66.84M | $65.78M | $66.14M | $54.76M | $53.01M | $71.79M | $53.82M | $48.20M | $50.99M | $65.26M | $60.34M | $45.81M | $44.61M | $59.33M | $30.03M | $31.33M | $31.16M | $15.95M | $28.51M | $28.52M | $27.41M | $44.41M | $27.02M | $27.41M | $27.93M | $20.49M | $21.14M | $793.82K |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.70% | 0.75% | 0.65% | 0.50% | 0.84% | 0.92% | 0.74% | 0.89% | 0.97% | 0.97% | 1.58% | 0.94% | 0.93% | 1.07% | 0.56% | 0.93% | 1.10% | 1.04% | 1.26% | 1.20% | 23.02% |
Collegium Pharmaceutical's average Quarter SG&A projection for Dec 23 is $54.45M, based on 3 Wall Street analysts, with a range of $53.82M to $54.78M. The forecast indicates a 54.27% rise compared to COLL last annual SG&A of $35.30M (Sep 23).
Collegium Pharmaceutical EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 6 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 12 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | $0.61 | $0.38 | $-0.51 | $-0.21 | $0.01 | $-0.15 | $-0.39 | $-0.73 | $0.23 | $2.06 | $0.45 | $0.20 | $0.33 | $0.23 | $-0.12 | $-0.07 | $-0.17 | $-0.13 | $-0.28 | $-0.74 | $-0.78 |
| Avg Forecast | $1.87 | $1.77 | $1.69 | $1.62 | $1.66 | $1.59 | $1.49 | $1.47 | $1.38 | $1.22 | $1.22 | $1.33 | $1.09 | $1.38 | $1.44 | $0.90 | $1.04 | $0.96 | $0.96 | $1.00 | $0.97 | $0.90 | $0.86 | $0.66 | $0.05 | $0.05 | $-0.04 | $-0.15 | $-0.41 | $-1.17 |
| High Forecast | $1.87 | $1.77 | $1.69 | $1.62 | $1.66 | $1.76 | $1.49 | $1.52 | $1.53 | $1.41 | $1.23 | $1.38 | $1.09 | $1.44 | $1.44 | $0.90 | $1.04 | $0.96 | $0.99 | $1.00 | $0.97 | $0.90 | $0.86 | $0.66 | $0.05 | $0.05 | $-0.04 | $-0.15 | $-0.33 | $-0.94 |
| Low Forecast | $1.87 | $1.77 | $1.69 | $1.62 | $1.66 | $1.46 | $1.49 | $1.42 | $1.19 | $1.10 | $1.21 | $1.28 | $1.09 | $1.33 | $1.44 | $0.90 | $1.04 | $0.96 | $0.94 | $1.00 | $0.97 | $0.90 | $0.86 | $0.66 | $0.05 | $0.05 | $-0.04 | $-0.15 | $-0.49 | $-1.40 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.31% | -0.38% | -0.19% | 0.01% | -0.10% | -0.44% | -0.70% | 0.24% | 2.14% | 0.45% | 0.21% | 0.37% | 0.27% | -0.18% | -1.44% | -3.22% | 2.89% | 1.90% | 1.80% | 0.67% |
According to 3 Wall Street analysts, Collegium Pharmaceutical's projected average Quarter EPS for Dec 23 is $1.38, with a low estimate of $1.19 and a high estimate of $1.53. This represents a 125.96% increase compared to COLL previous annual EPS of $0.61 (Sep 23).
Collegium Pharmaceutical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PROC | Procaps Group | $1.79 | $10.00 | 458.66% | - |
| PCRX | Pacira BioSciences | $16.57 | $40.00 | 141.40% | Hold |
| EOLS | Evolus | $16.75 | $24.00 | 43.28% | Buy |
| ANIP | ANI Pharmaceuticals | $58.19 | $79.00 | 35.76% | Buy |
| AMPH | Amphastar Pharmaceuticals | $50.73 | $66.00 | 30.10% | Buy |
| ALKS | Alkermes | $26.47 | $34.38 | 29.88% | Hold |
| COLL | Collegium Pharmaceutical | $33.46 | $41.50 | 24.03% | Buy |
| PBH | Prestige Consumer Healthcare | $74.05 | $82.00 | 10.74% | Buy |
| ITCI | Intra-Cellular Therapies | $86.54 | $94.50 | 9.20% | Buy |
| PAHC | Phibro Animal Health | $23.18 | $18.67 | -19.46% | Buy |
COLL Forecast FAQ
Is Collegium Pharmaceutical a good buy?
Yes, according to 8 Wall Street analysts, Collegium Pharmaceutical (COLL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 62.50% of COLL's total ratings.
What is COLL's price target?
Collegium Pharmaceutical (COLL) average price target is $41.5 with a range of $35 to $50, implying a 24.03% from its last price of $33.46. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Collegium Pharmaceutical stock go up soon?
According to Wall Street analysts' prediction for COLL stock, the company can go up by 24.03% (from the last price of $33.46 to the average price target of $41.5), up by 49.43% based on the highest stock price target, and up by 4.60% based on the lowest stock price target.
Can Collegium Pharmaceutical stock reach $50?
COLL's average twelve months analyst stock price target of $41.5 does not support the claim that Collegium Pharmaceutical can reach $50 in the near future.
What are Collegium Pharmaceutical's analysts' financial forecasts?
Collegium Pharmaceutical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $626.12M (high $640.74M, low $618.86M), average EBITDA is $97.15M (high $102.75M, low $92.8M), average net income is $169.65M (high $180.93M, low $159.93M), average SG&A $266.2M (high $289.42M, low $245.7M), and average EPS is $6.2 (high $6.43, low $6.02). COLL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $738.77M (high $738.77M, low $738.77M), average EBITDA is $125.36M (high $125.36M, low $125.36M), average net income is $280.59M (high $280.59M, low $280.59M), average SG&A $272.07M (high $272.07M, low $272.07M), and average EPS is $6.95 (high $6.95, low $6.95).
Did the COLL's actual financial results beat the analysts' financial forecasts?
Based on Collegium Pharmaceutical's last annual report (Dec 2022), the company's revenue was $463.93M, beating the average analysts forecast of $449.4M by 3.23%. Apple's EBITDA was $34.37M, beating the average prediction of $6.84M by 402.74%. The company's net income was $-25.002M, missing the average estimation of $25.2M by -199.23%. Apple's SG&A was $172.19M, missing the average forecast of $240M by -28.26%. Lastly, the company's EPS was $-0.74, missing the average prediction of $4.81 by -115.39%. In terms of the last quarterly report (Sep 2023), Collegium Pharmaceutical's revenue was $136.71M, missing the average analysts' forecast of $137.27M by -0.41%. The company's EBITDA was $45.01M, beating the average prediction of $23.29M by 93.25%. Collegium Pharmaceutical's net income was $20.63M, missing the average estimation of $49.19M by -58.06%. The company's SG&A was $35.3M, missing the average forecast of $50.55M by -30.18%. Lastly, the company's EPS was $0.61, missing the average prediction of $1.22 by -49.93%